Speed Dating, BIO-Style

A Fortune reporter considers whether a "marriage between pharma and biotech will create more drugs."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

In addition to a stifling

In addition to a stifling bureaucracy, big pharma has not been able to come up with a model to reward it scientists for high fail rates, which is the flip side of adopting innovative approaches. In this environment, scientists follow more conservative approaches for drug discovery; senior management criticizes the lack of internal creativity and looks to the biotech world to feed its pipeline. Of course big pharma will find that going with biotech alone is no panacea, as it has its own limitations.